MagicMed to Be Acquired by Nasdaq-Listed Company Post published:May 24, 2021 Post category:Analysis/News
MindMed Becomes Second Psychedelic Drug Development Company to List on the Nasdaq Post published:April 27, 2021 Post category:News
Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway Post published:March 2, 2021 Post category:Analysis/News
UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition Post published:January 27, 2021 Post category:Analysis/News
North American Psychedelics Index Published: Which Companies Will Be in the First Psychedelic ETF? Post published:January 21, 2021 Post category:Analysis/News
First Psychedelic ETF Expected to Launch January 2021 (NEO:PSYK) Post published:December 28, 2020 Post category:Analysis/News
Beckley Psytech Raises £14m ($18.6m) to Advance Development of 5-MeO-DMT for Neuropsychiatric Diseases Post published:December 19, 2020 Post category:News
Canada to Consider Allowing Psychedelic-Assisted Therapy under Special Access Program Amendment Post published:December 12, 2020 Post category:Analysis/News
UK Regulators Approve World’s First DMT for Depression Clinical Trial Post published:December 10, 2020 Post category:News
Research Suggests Past Antidepressant Usage Reduces Efficacy of MDMA-Assisted Psychotherapy for PTSD Post published:November 23, 2020 Post category:News